January 7, 2025
12:00 – 1:00 PM PST
Register Here

After participating in the activity, learners will gain insight into the various types and causes of neuropathy, with a focus on how these affect treatment approaches. They will be able to Identify key interventional techniques for managing neuropathy, including nerve blocks, spinal cord stimulation, and peripheral nerve stimulation. the presentation will help the participant evaluate the potential risks and benefits of interventional management options and how to mitigate adverse effects while gaining insights into emerging trends and technologies in interventional neuropathy treatment that may improve patient outcomes.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Describe common causes and presentations of neuropathy.

2. Describe a patient identification and diagnostic process.

3. Discuss treatment options for injections to implants.

Target Audience

This activity is designed to educate commission members, practitioners, medical regulatory staff, and the public.

Speaker Biography

Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Federation of State Medical Boards and the Washington Medical Commission. The Federation of State Medical Boards is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Federation of State Medical Boards designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Director
Gina Fino, MD
Washington Medical Commission

Commercial Support

This learning activity is not funded by any commercial entity.

Disclosure Declaration

As an organization accredited by the ACCME, the Federation of State Medical Boards (FSMB) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. All faculty, planners, and others in a position to control continuing medical education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Faculty (authors, presenters, speakers and planners) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

Faculty members are asked to disclose all financial relationships they have had in the past 24 months with ineligible companies regardless of the potential relevance of each relationship to the education and of the amount. The FSMB has implemented a mechanism to identify and resolve all  conflicts of interest prior to the activity. The intent of this policy is to identify potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. None of the planners, speakers, and/or panelists for this activity have relevant financial relationships to disclose with ineligible companies.

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Faculty and Staff Disclosures

No speaker or persons in control of content reported intent to reference unlabeled/unapproved uses of drugs or products.